Adamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Adamas Pharma (ADMS) Sees Red-to-Green Move
December 24, 2015 11:28 AM ESTAfter trading down as much as 8% earlier, yesterday's big mover Adamas Pharma (NASDAQ: ADMS) is back in positive territory.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit Suisse
December 24, 2015 7:37 AM ESTCredit Suisse analyst V. Divan reiterated an Outperform rating and raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $37.00 (from $35.00) after raising the probability of success for ADS-5102 to 90% (from 80%) on the back of encouraging topline phase 3 data for their lead internal asset... More
Adamas Pharma (ADMS) Ramps Into the Close
December 23, 2015 3:38 PM ESTAdamas Pharma (NASDAQ: ADMS) ramps into the close. Shares are up 73.6% and near the highs after earlier announcing statistically significant ADS-5102 Phase 3 EASE LID data.
... MoreAegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as Key
December 23, 2015 12:04 PM ESTAegis Capital reaffirmed its Buy rating and $29 price target on Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) after the company announced that its... More
Piper Jaffray Remains Bullish on Adamas Pharmaceuticals (ADMS)
December 23, 2015 9:12 AM ESTWhile no note was issued, Piper Jaffray's David Amsellem remains positive on Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) which is up over 30% premarket after its phase 3 trial for ADS-5102 (amantadine HCI) ER in Parkinson's (LID) meeting primary endpoint.
Adamas Pharma (ADMS) Announces Statistically Significant ADS-5102 Phase 3 EASE LID Data
December 23, 2015 6:20 AM ESTAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that its Phase 3 EASE LID clinical trial evaluating the companys investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinsons disease met its primary endpoint. Results from this randomized, placebo-controlled study showed a statistically significant reduction (p = 0.0009) in LID at 12 weeks for patients who received ADS-5102 versus placebo as assessed by the Unified Dyskinesia Rating Scale (UDysRS). This represents a 23 percent reduction in LID for ADS-5102-treated patients compared to placebo. The reduction in LID was maintained at 24 weeks (p =... More
